drugset / Trial / NCT04148573

Clinical Trial to Evaluate Safety, Tolerability and Efficacy of NFX88 in SCI

NCT04148573 ↗

Phase 2 Completed 44 enrolled Neurofix S.L.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

In summary, this small-scale study is designed to demonstrate that the NFX88 is safe and well tolerated, as well as preliminary evidence of improvement in the score of VAS, PD-Q, and PGIC scales.

Timeline

Start
2019-10-01
Primary completion
2022-05-20
Completion
2022-07-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator NFX88 Unknown 1.05 g Oral
Comparator NFX88 Unknown 2.1 g Oral
Comparator NFX88 Unknown 4.2 g Oral